Viking Therapeutics Stock Could Rocket 76% Higher – Is It Time to Buy?
Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage drugmaker focusing on metabolic treatments, have surged in value this year, with experts projecting even more growth on the horizon. The stock has caught the attention of analysts who believe it could rise to $113.55 per share, representing a potential gain of 76% from its recent closing price.
But before diving headfirst into this opportunity, investors should familiarize themselves with the experimental drugs in Viking Therapeutics’ late-stage pipeline that are driving this bullish sentiment on Wall Street.
Viking Therapeutics is currently in the process of advancing VK2735, an experimental treatment, to phase 3 trials. VK2735 is a weekly injection targeting GLP-1 and GIP receptors in the pancreas to reduce patients’ appetites. This unique approach has the potential to make VK2735 a blockbuster drug, positioning it in a market dominated by only a few players like Eli Lilly’s tirzepatide.
Eli Lilly’s tirzepatide, the only other treatment that targets both GLP-1 and GIP receptors, has seen significant success and market share growth, indicating the potential for similar success for VK2735.
In addition to VK2735, Viking Therapeutics is also developing VK2809 as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a liver condition affecting millions of Americans. With the recent launch of Rezdiffra by Madrigal Pharmaceuticals for MASH treatment, Viking’s VK2809 could soon follow suit pending FDA approval.
While the future looks promising for Viking Therapeutics, investors should remain cautious due to the high market cap of $7.2 billion and the potential risks associated with launching new drugs. Independent drug launches often fail to meet expectations, and the success of VK2735 and VK2809 hinges on numerous factors, including FDA approval.
With its strong cash position and ambitious pipeline, Viking Therapeutics presents a compelling opportunity for investors willing to tolerate some risk. However, prudent investors should exercise caution and consider the potential pitfalls associated with investing in clinical-stage biotech stocks.
Stay informed and make informed decisions when considering Viking Therapeutics as a prominent player in the biotech industry. Extreme Investor Network is your go-to source for in-depth analysis and expert insights on the latest trends and opportunities in the financial market. Trust us to provide you with the information you need to make sound investment decisions.